Insights on the Indian Long-Acting Bronchodilator Market to 2019 | Industry Statistics, Emerging Demands, Forecast to 2025

Indian long-acting bronchodilator market is anticipated to grow at a substantial rate of around 8.0% during the forecast period. Major factors that augments the growth of the market include large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and significant presence of market players in the country. The Indian long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the increasing pool of aging population susceptible to the high prevalence of asthma in the country.

To Request a Sample of our Report on Indian Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/indian-long-acting-bronchodilator-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within the region and across the globe. The major players of the Indian long-acting bronchodilator market include Cipla Ltd., AstraZeneca PLC, Aradigm Corp., GlaxoSmithKline PLC, Novartis AG, ResMed, Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players.

Cipla is one of the major companies working in the long-acting bronchodilator market. The company offers products in the field of asthma, COPD, Allergic Rhinitis (AR), Pulmonary Arterial Hypertension (PAH), lung cancer and Idiopathic Pulmonary Fibrosis (IPF). In May 2018, the company established a partnership with MannKind for marketing and distributing Afrezza. It is the only US FDA approved inhaled insulin available for patients suffering from diabetes. In addition, the company in February 2018, has entered into a partnership with Roche Pharma India for healthcare improvement and increasing access to life-changing medicines in India.

(Get 15% Discount on Buying this Report)

A full Report of Indian Long-Acting Bronchodilator Market is Available @ https://www.omrglobal.com/industry-reports/indian-long-acting-bronchodilator-market

Indian Long-Acting Bronchodilator Market Segmentation

By Route of Administration

· Oral

· Nasal

· Parenteral

· Inhalation

By Application

· Asthma

· Chronic Obstructive Pulmonary Disease (COPD)

By End-User

· Homecare

· Hospitals and Clinics

Company Profiles

· Adamis Pharmaceuticals Corp.

· AstraZeneca PLC

· eximo Pharmaceuticals Ltd.

· Boehringer Ingelheim International GmbH

· Cipla Ltd.

· GlaxoSmithKline PLC

· Novartis AG

· ResMed Corp.

· Pulmatrix Inc.

· Sunovion Pharmaceuticals

· Teijin Pharma Ltd.

· Teva Pharmaceuticals Industries Ltd.

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.